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Summary. Background: Little information is available on the
long-term clinical outcome of cerebral vein thrombosis
(CVT). Objectives and methods: In an international, retrospec-
tive cohort study, we assessed the long-term rates of mortality,
residual disability and recurrent venous thromboembolism
(VTE) in a cohort of patients with a ﬁrst CVT epi-
sode. Results: Seven hundred and six patients (73.7% females)
with CVT were included. Patients were followed for a total of
3171 patient-years. Median follow-up was 40 months (range 6,
297 months). At the end of follow-up, 20 patients had died
(2.8%). The outcome was generally good: 89.1% of patients
had a complete recovery (modiﬁed Rankin Score [mRS] 0–1)
and3.8%hadapartial recovery andwere independent (mRS2).
Eighty-four per cent of patients were treated with oral
anticoagulants and the mean treatment duration was
12 months. CVT recurred in 31 patients (4.4%), and 46 patients
(6.5%) had a VTE in a diﬀerent site, for an overall incidence of
recurrence of 23.6 events per 1000 patient-years (95% conﬁ-
dence Interval [CI] 17.8, 28.7) and of 35.1 events/1000 patient-
years (95% CI, 27.7, 44.4) after anticoagulant therapy with-
drawal. A previous VTE was the only signiﬁcant predictor of
recurrence at multivariate analysis (hazard ratio [HR] 2.70;
95% CI 1.25, 5.83). Conclusions: The long-term risk of
mortality and recurrent VTE appears to be low in patients
who survived the acute phase of CVT. A previous VTE history
independently predicts recurrent events.
Keywords: anticoagulant treatment, cerebral vein thrombosis,
mortality, recurrence.
Introduction
Cerebral vein thrombosis (CVT) has long been considered a
rare disease with important long-term morbidity and mortality
rates [1,2]. In the last decade, new non-invasive diagnostic
techniques have increased the frequency with which this disease
is diagnosed and there has been increasing evidence that an
early diagnosis and a timely start of anticoagulant treatment
signiﬁcantly reduced morbidity from CVT and improved
survival [3].
Recent guidelines recommend the use of unfractionated
heparin or low-molecular-weight heparin followed by at least
3–6 months of oral anticoagulant therapy (OAT) with vitamin
K antagonists for most patients with a ﬁrst episode of CVT
[4,5]. However, the optimal duration of anticoagulant treat-
ment is not established because little information is available on
the long-term rate of recurrent CVT or the rate of recurrence of
venous thromboembolic events (VTE) in other sites after the
discontinuation of anticoagulant drugs. These rates have been
reported to be low in a large prospective study [6], and these
ﬁndings were conﬁrmed by a subsequent meta-analysis that
included 19 studies for a total of about 1500 patients [7].
However, these results were based on relatively short periods of
follow-up. Furthermore, almost all published studies were too
small to evaluate potential risk factors for recurrence. More
recently, a large cohort study from a single center conﬁrmed the
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substantially low rate of recurrences after a longer-term follow-
up [8].
Thus, to better estimate the long-term recurrence rates of
CVT and to accurately identify risk factors for recurrence, we
conducted a large, international, multicenter, retrospective
cohort study in a population of patients with a ﬁrst episode of
CVT.
Methods
The study involved 27 centers from Italy, Czech Republic and
the USA. The complete list of participating centers is available
in Appendix 1.
All centers were Thrombosis Units, Anticoagulation Clinics
or Neurology Clinics. These centers are routinely involved in
the management of CVT patients from the time of diagnosis
and the start of anticoagulant treatment or are subsequently
involved in the monitoring of OAT and the evaluation of
speciﬁc risk factors, such as thrombophilia, after the ﬁrst days
of acute treatment. All involved centers regularly perform long-
term follow-up of these patients.
At each participating center, data on consecutive cases of
patients with a ﬁrst episode of objectively diagnosed CVT were
collected. All eligible patients have been regularly followed by
the local anticoagulation clinics and/or by neurology clinics/
stroke units. As the main aim of the study was to evaluate the
clinical history of CVT, only patients with an available follow-
up of at least 6 months or with an outcome event occurring
within the ﬁrst 6 months (death, recurrence of CVT and
occurrence of VTE) were included in the study. However, to
explore the presence of potential differences in the population
with and without follow-up, their baseline characteristics were
compared.
Case report forms were prepared by the coordinating center
(Varese, Italy) and were sent to all participating centers. Local
investigators were asked to ﬁll out the form and to send it back
to the coordinating center. All data were cross-checked and
validated centrally at the end of the follow-up period.
Demographic data, site of thrombosis, medical history
focusing on potential risk factors for thrombosis, treatment
and clinical outcome were gathered. Furthermore, information
on family and a personal history of VTE was also collected. A
positive personal history of VTE was adjudicated if the patient
had a previous objectively assessed episode of a deep vein
thrombosis, pulmonary embolism, splanchnic vein thrombosis
or CVT. A positive family history of VTE was adjudicated
when one or more ﬁrst-degree relatives had an objectively
assessed episode of VTE.
Cerebral vein thrombosis was deﬁned as secondary in the
presence of one of the following risk factors: cancer, infections,
trauma, oral contraceptive (OC) use, pregnancy, puerperium,
hormone replacement therapy (HRT), neurosurgery and
myeloproliferative neoplasms. In the absence of the aforemen-
tioned predisposing factors, the CVT episode was deﬁned as
unprovoked. Information on thrombophilic abnormalities,
including antithrombin, proteins C and S, factor V Leiden, and
G20210A mutations, homocysteine, lupus anticoagulant, an-
ticardiolipin antibodies, antibeta2glycoprotein I antibodies
were collected when available.
Information on clinical events during follow-up was ﬁrst
collected using the computerized database of each anticoagu-
lation clinic or neurology department, where data on patients
outcomes are regularly collected. Furthermore, for the purpose
of this study and in order to guarantee the most accurate and
updated information, investigators were requested to contact
all included patients by means of a visit at the center, a
telephone contact, or a mailed questionnaire if this was not
scheduled during their regular clinical activity. At the time of
contact, information on CVT recurrence, on the occurrence of
VTE in other sites, and on the death of the patient was collected
and was added to the information stored at each center
database. For all reported events, accurate evaluation of source
documentation was requested. Only objectively diagnosed
events were considered. Accepted tests were the following:
magnetic resonance (MR) imaging with MR venography,
computed tomography (CT) venography, or conventional
angiography for the diagnosis of recurrent CVT; compressive
B-mode ultrasound or echo-color Doppler for the diagnosis of
lower or upper extremity deep vein thrombosis; perfusion or
ventilation/perfusion lung scan or helical-computed tomogra-
phy for the diagnosis of pulmonary embolism. Adjudication of
CVT recurrence after objective testing was performed locally at
each participating center.
Finally, information on the cause of death was requested.
The following data were also recorded for this study: the
presence of residual disability at the time of the last patient
contact (deﬁned according to the modiﬁed Rankin Scale
[mRS]) [9] and current and previous antithrombotic treatments.
Residual disability was classiﬁed according to the mRS as
complete recovery (mRS 0–1); partial recovery, independent
(mRS 2); dependent (mRS 3–5); and death (mRS 6).
The Institutional Review Board approved the study, which
was carried out and is reported according to the Strengthening
the Reporting of observational Studies in Epidemiology
(STROBE) guidelines for observational studies [10].
Continuous variables were expressed as mean plus or minus
the standard deviation (SD) or as median with minimum and
maximum values when data did not have a normal distribu-
tion; categorical data are given as counts and percentages. The
annual incidence of recurrent thrombosis was calculated for the
whole group of venous thromboses and then separately for
CVT and VTE in other sites by dividing the number of events
by the total number of patient-years followed until the VTE or
death. To explore the potential role of anticoagulant therapy
on the risk of recurrent thrombosis, separate data of the risk of
recurrence during anticoagulation and after anticoagulation
discontinuation were provided. The 95% conﬁdence intervals
(CIs) were based on the exact approximation of the Poisson
distribution. Because of the low recurrence rates of VTE, when
the analysis was limited to speciﬁc subgroups, only crude
estimates of the incidence were given. Recurrence-free survival
was calculated using the Kaplan–Meier method [11]. The role
1298 F. Dentali et al
 2012 International Society on Thrombosis and Haemostasis
of potential risk factors for thrombosis recurrence was
evaluated using the Cox proportional-hazard model [12]. All
the potential risk factors for VTE were introduced in the Cox
model. The impact of different severities of thrombophilia was
analyzed.
Severe thrombophilia was deﬁned as the presence of
antithrombin, protein C or protein S deﬁciency, antiphosphol-
ipid antibodies and by the concomitant presence of more than
one abnormality [13]. As a ﬁrst step, the risk of thrombosis
recurrence in patients with thrombophilia was compared with
that of patients without thrombophilia. Subsequently, the risk
of thrombosis recurrence in patients with severe thrombophilia
was compared with that of patients without severe thrombo-
philia. We ﬁrst gave unadjusted hazard ratios (HRs) estimates
and then we adjusted the estimates for other possible
confounders. A P-valued of < 0.05 was chosen as the cut off
for statistical signiﬁcance. All statistical analyzes were per-
formed with SPSS 11.0 for Windows.
Results
Seven hundred and 41 patients with a ﬁrst episode of CVTwere
considered for inclusion during the study period. For 35
patients (4.9%) the duration of follow-up was insufﬁcient
(< 6 months) and these patients were excluded from the
analysis. Baseline characteristics of patients with and without a
sufﬁcient follow-upwere not different (data not shown). Hence,
706 patients (mean age 40.0 ± 16.3 years) were included in the
study. Baseline demographic and clinical characteristics, and
potential risk factors for CVT are listed in Table 1.
Four hundred and two patients (55.8%) had at least one risk
factor, whereas in 304 patients (44.2%) CVT was idiopathic.
Signiﬁcantly more women had at least one risk factor
compared with men (61.0% vs. 45.7%; P < 0.05). As not all
thrombophilic abnormalities were tested in all of the patients,
we provided separate results for each thrombophilic abnor-
mality (see the Appendix Table A1).
The median duration of anticoagulant treatment was
12 months and 134 patients (19.0%) were still on OAT at the
time of the last contact. The median duration of follow-up was
40 months (range 1–297 months) for a total follow-up of 3171
patient-years. Total follow-up during anticoagulation was 1143
patient-years and after anticoagulation discontinuation was
2028 patient-years.
The outcome of these patients was generally good: 89.1% of
patients had a complete recovery (mRS 0–1) and 3.8% had a
partial recovery and were independent (mRS 2). Over the time
period of this study, there were 20 deaths in patients with CVT
for a mortality rate of 2.8%. The cause of death was most
commonlymalignancy related (n = 12). Other causes included
consequences of CVT (n = 2), arterial stroke (n = 2), fatal
arrhythmia (n = 1), hepatic failure (n = 1) and sepsis
(n = 1). In one patient the cause of death was unknown.
Three deaths occurred within 1 month. Patients with a
concomitant intracranial hemorrhage at presentation had a
slightly, but not signiﬁcant worse prognosis (mRS ‡ 3) at the
end of follow-up in comparison with patients without con-
comitant intracranial hemorrhage at presentation (9.1% vs.
7.1%; P 0.42). The estimated survival was 98% at 1 year and
95% at 5 years.
Seventy-ﬁve patients (10.6%) were diagnosed with recurrent,
non-fatal VTE. Clinical characteristics of patients with VTE
recurrence are listed in Table 2. Recurrent events included
recurrent CVT in 31 patients (4.4%) and VTE in other sites in
the remaining 46 patients (6.5%). Two patients had a VTE and
a concomitant recurrence of CVT. VTE in other sites occurred
in the lower limbs in 30 patients, in the pulmonary arteries in six
patients and in the lower limbs and pulmonary arteries at the
same time in seven patients. Finally, three patients had a
splanchnic vein thrombosis and 1 had a thrombosis of the
upper limbs. Recurrence-free survival using the Kaplan–Meier
method is represented in Fig. 1. The overall incidence of
recurrent VTE was 23.6 per 1000 patient-years (95% CI 17.8–
28.7). Most events occurred after anticoagulation discontinu-
ation for an incidence of recurrence in this group of 35.1 events/
1000 patient-years (95% CI, 27.7, 44.4). The recurrence rate
was similar in patients with unprovoked CVT and in patients
with CVT secondary to a known risk factors (22.8 events/1000
patient-years, 95% CI 15.9, 32.6 vs. 27.0 events/1000 patient-
years, 95% CI 20.4, 36.0).
Table 1 Baseline demographic and clinical characteristics, and potential
risk factors for recurrence of included patients
Total number, n 706
Male gender, n (%) 186 (26.3)
Mean age, years (± SD) 40.0 (16.3)
Principal sites of
thrombosis, n (%)
Superior sagittal sinus 267 (37.8)
Left lateral sinus 281 (39.8)
Right lateral sinus 225 (31.9)
Concomitant
intracranial
hemorrhage, n (%)
197 (27.9)
Risk factors at
ﬁrst CVT, n (%)
Infections 59 (8.3)
Trauma 18 (2.5)
OC or HRT 278 (39.4)
Pregnancy/puerperium 55 (7.8)
Cancer or MPD 52 (7.4)
Thrombophilic abnormalities
(one at least) 290 (41.1)
Severe thrombophilic
abnormalities 83 (11.7)
Unprovoked 312 (44.2)
Personal history of VTE, n (%) 54 (7.6)
Family history of VTE, n (%) 109 (15.4)
Acute antithrombotic
therapy, n (%)
LMWH 443 (62.7)
UFH 155 (21.9)
Thrombolysis 11 (1.5)
None 97 (13.7)
Post acute antithrombotic
therapy, n (%)
Oral anticoagulants 590 (83.6)
LMWH 37 (5.2)
Acetyl salicylic acid 14 (2.0)
None 62 (6.9)
CVT, cerebral vein thrombosis; HRT, hormone replacement therapy;
LMWH, low-molecular-weight heparin; MPD, myeloproliferative
disease; OC, oral contraceptives; UFH, unfractionated heparin; VTE,
venous thromboembolic events.
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Cox proportional hazards models were ﬁtted to identify
covariates associated with time to VTE in patients with CVT.
In the univariate model, a personal history of VTE (HR 2.73,
95% CI 1.53–4.89; P < 0.001), recent head trauma (HR 4.20,
95%CI 1.93–9.15; P < 0.001) and cancer (HR 2.57, 95% CI
0.91, 3.95; P < 0.012) were associated with recurrent VTE.
Thrombophilia and severe thrombophilia were not associated
with an increased risk of VTE recurrence. As a result of the
controversial role of hyperhomocysteinaemia, we repeated the
analysis excluding this thrombophilic abnormality; however,
the results did not change (data not shown). Indeﬁnite OAT
was not associated with improved event free survival (Table 3).
When all potential risk variables were included in a multivar-
iate model, only a personal history of VTE remained signif-
icantly associated with recurrent CVT or VTE in other sites
(HR 2.70; 95% CI 1.25–5.83; P < 0.011).
Discussion
To our knowledge, this is the largest multicenter cohort study
with an adequately long follow-up to evaluate the clinical
history of patients with a ﬁrst episode of CVT.
The principal ﬁnding of this study is in the estimate of
anticipated rates of recurrent venous thromboembolic events,
either CVT or VTE in other sites. During more than 3000
patient-years of follow-up, there were 31 episodes of CVT
recurrence and 46 episodes of VTE in other sites, with an
overall rate of 23.6 per 1000 patient-years and this rate was
similar in patients with unprovoked CVT and in patients with
CVT secondary to known risk factors. When recurrences were
assessed only after OAT was stopped, the incidence rate was
only slightly higher (35.1 events/1000 patient-years). These
results provide a robust conﬁrmation of previous observations
[6,8]. In the International Study on Cerebral Vein and Dural
Sinus Thrombosis (ISCVT), the investigators observed 14
recurrent CVT events (2.2%) and 19 lower limb deep vein
thrombosis or pulmonary embolism (3.0%) over a median
follow-up period of 16 months [6]. More recently, Martinelli
et al. [8] found an event rate of 2.03 per 100 patient-years in a
population of 145 patients with a ﬁrst episode of CVT.
Although only a minority of patients were treated life long,
substantially low rates of recurrent events were observed in this
study. After multivariate analysis, a previous VTE, but not the
duration of OAT, was associated with the risk of recurrence
suggesting that long-term OAT may be not necessary in most
CVT patients. Furthermore, in this study the presence of
thrombophilia did not appear to be associated with an
increased risk of VTE recurrence. This may be as a result of
Table 2 Characteristics of patients with VTE recurrence
Total VTE recurrence, n 75
Mean Age, year (± SD) 36.9 (13.8)
Male gender, n (%) 22 (29.3)
CVT recurrence, n (%) 31 (4.4)
VTE (splanchnic thrombosis,
deep venous thrombosis,
pulmonary embolism)
recurrence, n (%)
46 (6.5)
Principal sites of
thrombosis, n (%)*
Superior sagittal sinus 40 (53.3)
Left lateral sinus 29 (38.7)
Right lateral sinus 26 (34.7)
Concomitant intracranial
haemorrhage, n (%)
19 (25.3)
Risk factors at ﬁrst CVT, n (%) Infections 4 (5.3)
Trauma 7 (9.3)
OC or HRT 26 (34.7)
Pregnancy/puerperium 8 (10.7)
Cancer or MPD 8 (10.7)
Thrombophilic abnormalities
(one at least) 35 (46.7)
Severe thrombophilic
abnormalities (14.7)
Idiopathic 30 (37.3)
Personal history of VTE, n (%) 14 (18.7)
Family history of VTE, n (%) 14 (18.7)
Two patients had both the recurrences. CVT, cerebral vein thrombosis;
HRT, hormone replacement therapy; LMWH, low-molecular-weight
heparin; MPD, myeloproliferative disease; OC, oral contraceptives;
UFH, unfractionated heparin; VTE, venous thromboembolic events.
*More than one site was involved in some patients.
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Fig. 1. Recurrence-free survival using the Kaplan–Meier method.
Table 3 Association of baseline characteristics and potential risk factor
for recurrent VTE at univariate analysis
HR 95% CI P
Age at diagnosis 1.00 0.98–1.01 0.578
Gender 1.37 0.83–2.25 0.221
Personal history of VTE 2.73 1.53–4.89 0.001
Family history of VTE 1.14 0.63–2.00 0.669
Unprovoked presentation 1.02 0.61–1.69 0.926
Thrombophilic abnormalities 1.11 0.71–1.75 0.648
Severe thrombophilic abnormalities 1.16 0.61–2.20 0.654
OC/HRT 0.72 0.45–1.14 0.161
Cancer 2.57 0.91–3.95 0.012
Recent neurosurgery 1.71 0.24–12.4 0.594
Recent head trauma 4.20 1.93–9.15 < 0.001
Local or systemic infection 0.67 0.21–1.60 0.436
Myeloproliferative disease 2.03 0.28–14.60 0.483
Pregnancy/puerperium 1.05 0.48–2.28 0.911
Long-term anticoagulant therapy 1.13 0.65–1.95 0.664
HR, hazard ratio; CI, conﬁdence interval.
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a marginal effect of thrombophilic abnormalities on the risk of
VTE recurrence, although other potential confounding factors,
such as a different duration of anticoagulation in patients with
speciﬁc thrombophilic abnormalities, could not be excluded.
Thus, the role of thrombophila in CVT patients remains to be
established. Many recurrent VTE occurred in women in which
the ﬁrst CVT occurred during pregnancy or puerperium or was
secondary to OC or HRT use. However, neither female gender
nor pregnancy/puerperium or the use of OC/HRT appeared to
be an independent risk of VTE recurrence. Two previous
studies have evaluated potential risk factors for recurrence in
CVTpatients [8,14]. In the study byGosk-Bierska et al. [14], no
variable was signiﬁcantly associated with recurrent venous
thrombosis in these patients, whereas in the study conducted by
Martinelli et al. [8], risk factors for recurrent venous thrombo-
sis were male gender and, for recurrence of VTE in other sites
only, severe thrombophilia. These differences across studies
may be because of differences in patient selection and to the
smaller sample of the previous studies. For example, in the
single center study by Martinelli et al. [8], all patients were
referred for thrombophilia work-up and for counseling on the
secondary prevention of VTE. In our study, participating
centers had more heterogeneous roles in the management of
CVT patients. Furthermore, taken together, the two studies by
Gosk-Bierska and Martinelli enrolled a total of approximately
300 patients and may be underpowered to detect potential risk
factors for recurrence.
This study also conﬁrmed that most patients with CVT have
a more benign prognosis than previously suspected: only 2.8%
of patients had died at the end of the follow-up period and
most surviving patients recovered completely or had only mild
functional or cognitive deﬁcit. This may be as a consequence of
several factors. First, more sensitive diagnostic techniques have
undoubtedly led to the detection of smaller thrombi, which
probably have better prognosis. Second, older series included a
higher proportion of patients with infection-associated CVT;
these events are now less and less common as a result of the
widespread use of antibiotics. Third, the widespread use of
anticoagulant drugs for the acute and the long-term treatment
of CVT has certainly contributed to improve the natural
history of this disease. During follow-up, most patients had
died as a result of underlying conditions such as cancer.
Although a formal comparison was not possible, CVT
patients appear to have a lower risk of VTE recurrence in
comparison to patients withDVT or PE [15]. This low riskmay
explain why many established risk factors for VTE recurrence
in patients with a DVT or PE are not signiﬁcant in CVT
patients. Furthermore, these patients seem to have a more
benign prognosis compared with patients with usual site
thrombosis [15]. Differences in the baseline characteristics and
in the concomitant diseases among these two populations may
explain these results.
The present study has some limitations. First, the design of
the study is retrospective. However, to overcome at least some
of the limitations that are intrinsic to retrospective studies, we
only involved centers where patients are regularly monitored
and followed up, and to avoid misleading results we paid
meticulous attention in the ascertainment of the reported
outcome events and only patients with adequate quality of data
or with available sources of documentation to complete
missing information were considered eligible for inclusion.
Second, a referral bias could not be excluded as we mainly
enrolled patients whowere started onOAT. Thus, the results of
this study on the long-term outcome of the disease may not
completely apply to the whole population of patients with
CVT, as patients who died during the acute phase of the disease
and patients who were deemed ineligible for long-term
secondary prevention with anticoagulant drugs may be insuf-
ﬁciently represented. However, based on the results of previous
studies [6,7] these patients should represent a small minority of
CVT patients. Third, screening for thrombophilia was not
systematically performed in all the patients. Thus, although the
risk of recurrence in patients with mild thrombophilia did not
appear to be increased, the results of this study on the role of
thrombophilia should be interpreted with caution. Fourth, we
have no reliable data on the recanalization rate in the whole
group of CVT patients. Thus, we could not comment on its
potential inﬂuence on the risk of VTE recurrence. Last and
more important, a minority of patients with massive hemor-
rhages or other severe presentations may not have been
included in this study as these patients may not be referred to
the Thrombosis Units or Anticoagulation or Neurological
Clinics. Thus, our population may have a slightly better
prognosis compared with the general population of patients
with CVT.
On the other hand, study strengths include the long duration
of follow-up, both during anticoagulant treatment and after
anticoagulant treatment withdrawal, and the large sample size
of this cohort of patients, who had CVT diagnosed with
objective methods and who were followed up homogeneously
in a high number of centers.
In conclusion, the long-term risk of CVT recurrence and of
VTE in other sites appears to be low in patients with a ﬁrst
episode of CVT, regardless of the duration of treatment. This
risk appeared to be increased only in patients with previous
VTE. The long-term prognosis of CVT in terms of mortality
and residual disability is favorable in patients who survive the
acute phase of disease.
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Table A1: Number of patients tested and results for each
thrombophilic abnormality.
Thrombophilic abnormality Tested, N (%) Positive, N (%)
Total (one at least) (%) 627 (88.8) 290 (46.3)
Factor V Leiden, n (%) 560 (79.3) 51 (9.1)
G20210A prothrombin mutation 551 (78.0) 105 (19.1)
Protein C deﬁciency 552 (78.2) 18 (3.3)
Protein S deﬁciency 550 (77.8) 18 (3.3)
Antithrombin deﬁciency 564 (79.9) 11 (2.0)
Lupus anticoagulant 554 (78.5) 28 (5.1)
Anticardiolipin antibodies 556 (78.8) 18 (3.3)
Hyperhomocysteinemia 546 (77.3) 69 (12.6)
JAK2 V617F mutation 131 (25.9) 17 (13.0)
References
1 Ameri A, BousserMG. Cerebral venous thrombosis.Neurol Clin 1992;
10: 87–111.
2 Gates PC. Cerebral venous thrombosis. A retrospective review.Aust N
Z J Med 1986; 16: 766–70.
3 Dentali F, AgenoW.Natural history of cerebral vein thrombosis.Curr
Opin Pulm Med 2007; 13: 372–6.
4 Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K,
Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC,
Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH,
Tomsick T, American Heart Association/American Stroke Associa-
tion Council on Stroke; Council on Cardiovascular Radiology Inter-
vention; American Academy of Neurology. Guidelines for prevention
of stroke in patients with ischemic stroke or transient ischemic attack: a
statement for healthcare professionals from the American Heart
Association/American Stroke Association Council on Stroke: co-
sponsored by the Council on Cardiovascular Radiology and Inter-
vention: the American Academy of Neurology aﬃrms the value of this
guideline. Circulation 2006; 113: e409–49.
5 Einha¨upl K, Stam J, BousserMG, De Bruijn SF, Ferro JM,Martinelli
I, Masuhr F. EFNS guideline on the treatment of cerebral venous and
sinus thrombosis in adult patients. Eur J Neurol 2010; 17: 1229–35.
6 Ferro JM, Canha˜o P, Stam J, Bousser MG, Barinagarrementeria F,
ISCVT Investigators. Prognosis of cerebral vein and dural sinus
thrombosis: results of the International Study on Cerebral Vein and
Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35: 664–70.
7 Dentali F, Gianni M, Crowther MA, Ageno W. Natural history of
cerebral vein thrombosis: a systematic review. Blood 2006; 108: 1129–
34.
8 Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E,
Mannucci PM. Long-term evaluation of the risk of recurrence after
cerebral sinus-venous thrombosis. Circulation 2010; 121: 2740–6.
9 Bamford JM, Sandercock PA, Warlow CP, Slattery J. Interobserver
agreement for the assessment of handicap in stroke patients. Stroke
1989; 20: 828.
10 Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow
CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M for the STROBE
Initiative. Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE): explanation and elaboration. Ann Intern
Med 2007; 147: W-163–94.
11 Kaplan EL, Meier P. Nonparametric estimation from incomplete
observations. J Am Stat Assoc 1958; 53: 457–81.
12 Rao SR, Schoenfeld DA. Survival methods. Circulation 2007; 115:
109–13.
13 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis.
N Engl J Med 2001; 344: 1222–31.
14 Gosk-Bierska I, Wysokinski W, Brown RD Jr, Karnicki K, Grill D,
Wiste H, Wysokinska E, McBane RD. 2nd Cerebral venous sinus
thrombosis: incidence of venous thrombosis recurrence and survival.
Neurology 2006; 67: 814–9.
15 Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesa-
vento R, Iotti M, Tormene D, Simioni P, Pagnan A. The risk of
recurrent venous thromboembolism after discontinuing anticoagula-
tion in patients with acute proximal deep vein thrombosis or pulmo-
nary embolism. A prospective cohort study in 1626 patients.
Haematologica 2007; 92: 199–205.
1302 F. Dentali et al
 2012 International Society on Thrombosis and Haemostasis
